Citadel Advisors’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Citadel Advisors’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-500	Closed	-$5.02K	–	15785
2023 Q4	$5.02K	Buy	+500	New	+$2.27K	﹤0.01%	13463

Citadel Advisors's GRCL Position: Q1 2024 in Review

Citadel Advisors sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 57,801 shares — an estimated $580K sold.

Citadel Advisors first reported a position in GRCL in Q1 2021 and held it in 5 quarters. The position peaked at $596K in Q1 2021. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Citadel Advisors reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 57,801 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $580K.
Citadel Advisors first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 5 quarters.
Citadel Advisors's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $596K in Q1 2021.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.